n3D’s goal is to develop market-leading 3D cell-culturing products for life science research and development, toxicity assays, drug discovery, and regenerative medicine.

 

This vision will be realized in near, mid, and long-term stages:

 

 

Near-term. This phase will provide cell-culturing solutions for life science research and development laboratories, which will yield initial revenue and market validation, and establish brand identity. One MD Anderson laboratory is already using the Bio-Assembler™, and n3D will market the technology throughout the local Houston area as soon as licensing agreements are in place. The Bio-Assembler™ can also form the basis of toxicity assays that can be used for cosmetics, pharmaceutical, and environmental applications.

 

Mid-term. The mid-term strategy is to adapt and market n3D’s technology for industrial-scale applications in drug discovery. Because of the Bio-Assembler™’s high-throughput potential and its better representation of in vivo tissue, this platform can replace 2D culturing as the standard for the initial phases of drug discovery. This can be accomplished by creating a large-scale, high-throughput version of the Bio-Assembler™ and partnering with an automated culturing and screening device manufacturer to offer a complete solution.

 

Long-term. The Bio-Assembler™ represents a new paradigm in scaffoldless cell culturing with temporal and spatial control of tissue structure. This has great potential for regenerative medicine and stem cell therapy. Research conducted with the support of federal grants or long-horizon venture funding will optimize the basic Bio-Assembler™ device and establish the procedures necessary for growing specific tissue types. This will consolidate an intellectual property position, after which n3D will seek a partner with clinical and tissue engineering expertise in these areas to develop products for therapeutic applications.